Skip to content

Aerie Pharmaceuticals, Inc.

CIK 0001337553

← back to feed
Revenue (TTM)
$128.59M
+686.5% YoY Q3 Oct 2022
Net Income (TTM)
−$121.78M
−62.1% YoY Q3 Oct 2022
EPS Diluted (TTM)
−$2.59
+59.6% YoY Q3 Oct 2022
Gross Margin
80.3%
Q3 Oct 2022
Operating Margin
-86.2%
Q3 Oct 2022
Net Margin
-94.7%
Q3 Oct 2022
Free Cash Flow (TTM)
−$67.15M
Q3 Oct 2022
Cash
$54.09M
Q3 Oct 2022
Total Debt
$0
Q3 Oct 2022
Shares Outstanding
49.42M sh
Q3 Oct 2022

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings